Five-Year Real-World Safety of Inotuzumab Ozogamicin Before Hematopoietic Stem Cell Transplantation in B-Cell Precursor Acute Lymphoblastic Leukemia.
作者信息
de Lima Marcos, Kebriaei Partow, Lanza Francesco, Cho Christina, Popradi Gizelle, Kaur Manmeet, Zhang Mei-Jie, Zhang Fan, Shah Richa, Vandendries Erik, Asomaning Kofi, Dorman Stephanie, Stelljes Matthias, Marks David I, Saber Wael
机构信息
Blood and Marrow and Cellular Therapy Program, Ohio State University, Columbus, Ohio, USA.
MD Anderson Cancer Center, Houston, Texas, USA.
出版信息
Am J Hematol. 2025 May;100(5):909-912. doi: 10.1002/ajh.27637. Epub 2025 Feb 24.
Abstract
摘要
相似文献
1
Five-Year Real-World Safety of Inotuzumab Ozogamicin Before Hematopoietic Stem Cell Transplantation in B-Cell Precursor Acute Lymphoblastic Leukemia.B细胞前体急性淋巴细胞白血病患者造血干细胞移植前使用奥英妥珠单抗的五年真实世界安全性
Am J Hematol. 2025 May;100(5):909-912. doi: 10.1002/ajh.27637. Epub 2025 Feb 24.
2
Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin.异基因造血干细胞移植受者中既往暴露于吉妥珠单抗奥佐米星或伊妥珠单抗奥佐米星后的肝静脉闭塞病。
Leuk Lymphoma. 2021 Feb;62(2):257-263. doi: 10.1080/10428194.2020.1827247. Epub 2020 Sep 29.
3
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.依妥珠单抗奥滨尤妥珠单抗对比既往治疗复发或难治性急性淋巴细胞白血病：来自随机、3 期 INO-VATE 研究的最终报告和长期生存随访。
Cancer. 2019 Jul 15;125(14):2474-2487. doi: 10.1002/cncr.32116. Epub 2019 Mar 28.
4
Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease.在异基因造血干细胞移植前复发或难治性急性 B 细胞淋巴细胞白血病患者中伊妥珠单抗奥滨尤妥珠单抗对结局的影响及窦状隙阻塞综合征/静脉阻塞性疾病的风险。
Haematologica. 2024 May 1;109(5):1385-1392. doi: 10.3324/haematol.2023.284310.
5
Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis.Blinatumomab 或 Inotuzumab Ozogamicin 桥接异基因造血干细胞移植治疗复发/难治性 B 系急性淋巴细胞白血病：回顾性单中心分析。
Clin Lymphoma Myeloma Leuk. 2020 Oct;20(10):e724-e733. doi: 10.1016/j.clml.2020.05.022. Epub 2020 Jun 3.
6
Atypical features of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after inotuzumab ozogamicin in adult patients with acute lymphoblastic leukemia.英妥昔单抗奥佐米星治疗成年急性淋巴细胞白血病患者后肝静脉闭塞性疾病/窦性阻塞综合征的非典型特征
Blood Res. 2025 Apr 22;60(1):28. doi: 10.1007/s44313-025-00077-3.
7
A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation.一组接受奥英妥珠单抗治疗的急性淋巴细胞白血病患者在异基因造血细胞移植后复发的病例系列。
Int J Hematol. 2022 Jan;115(1):69-76. doi: 10.1007/s12185-021-03217-4. Epub 2021 Sep 6.
8
Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia.奥英妥珠单抗在复发/难治性急性淋巴细胞白血病治疗中的作用。
Immunotherapy. 2016 Feb;8(2):135-43. doi: 10.2217/imt.15.108. Epub 2016 Jan 18.
9
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial.挽救性化疗免疫治疗联合 Inotuzumab Ozogamicin 联合 Mini-Hyper-CVD 治疗费城染色体阴性复发或难治性急性淋巴细胞白血病患者：一项 2 期临床试验。
JAMA Oncol. 2018 Feb 1;4(2):230-234. doi: 10.1001/jamaoncol.2017.2380.
10
Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions.依妥珠单抗奥滨尤妥珠单抗治疗成人急性淋巴细胞白血病：研发历程、现状与未来方向
Cancer. 2024 Nov 1;130(21):3631-3646. doi: 10.1002/cncr.35505. Epub 2024 Aug 2.
本文引用的文献
1
Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a refined classification from the European society for blood and marrow transplantation (EBMT).成年患者肝窦阻塞综合征/静脉闭塞性疾病的诊断和严重程度标准：欧洲血液与骨髓移植学会（EBMT）的细化分类
Bone Marrow Transplant. 2023 Jul;58(7):749-754. doi: 10.1038/s41409-023-01992-8. Epub 2023 Apr 24.
2
Diagnosis and Treatment of VOD/SOS After Allogeneic Hematopoietic Stem Cell Transplantation.异基因造血干细胞移植后 VOD/SOS 的诊断与治疗。
Front Immunol. 2020 Apr 3;11:489. doi: 10.3389/fimmu.2020.00489. eCollection 2020.
3
Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia.奥加米妥珠单抗治疗复发或难治性急性淋巴细胞白血病后的异基因造血干细胞移植的结果。
Biol Blood Marrow Transplant. 2019 Sep;25(9):1720-1729. doi: 10.1016/j.bbmt.2019.04.020. Epub 2019 Apr 27.
4
Management of important adverse events associated with inotuzumab ozogamicin: expert panel review.与奥英妥珠单抗相关的重要不良事件的管理：专家小组审查
Bone Marrow Transplant. 2018 Apr;53(4):449-456. doi: 10.1038/s41409-017-0019-y. Epub 2018 Jan 12.
5
Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.奥英妥珠单抗治疗复发或难治性急性淋巴细胞白血病成年患者的肝脏不良事件情况：开放标签、随机、3期INO-VATE研究结果
Lancet Haematol. 2017 Aug;4(8):e387-e398. doi: 10.1016/S2352-3026(17)30103-5. Epub 2017 Jul 4.
6
Acute lymphoblastic leukemia: a comprehensive review and 2017 update.急性淋巴细胞白血病：全面综述及2017年更新
Blood Cancer J. 2017 Jun 30;7(6):e577. doi: 10.1038/bcj.2017.53.
7
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.奥英妥珠单抗对比标准疗法治疗急性淋巴细胞白血病
N Engl J Med. 2016 Aug 25;375(8):740-53. doi: 10.1056/NEJMoa1509277. Epub 2016 Jun 12.
Zotero 插件